LABP Stock Price, Landos Biopharma, Inc. Quote, Chart

Market Summary

USD22.31-0.18

Market Closed

-0.80%

LABP Stock Price

View Fullscreen

LABP RSI Chart

LABP Valuation

Market Cap

69.5M

Price/Earnings (Trailing)

-3.17

Price/Sales (Trailing)

3.78

EV/EBITDA

-1.52

Price/Free Cashflow

-3.4

LABP Price/Sales (Trailing)

LABP Profitability

EBT Margin

-121.86%

Return on Equity

-69%

Return on Assets

-57.66%

Free Cashflow Yield

-29.45%

LABP Fundamentals

LABP Revenue

Revenue (TTM)

18.0M

LABP Earnings

Earnings (TTM)

-21.9M

Earnings Growth (Yr)

-16.95%

Earnings Growth (Qtr)

-4.42%

Breaking Down LABP Revenue

Last 7 days

2.3%

Last 30 days

4.5%

Last 90 days

384.0%

Trailing 12 Months

7867.9%

How does LABP drawdown profile look like?

LABP Financial Health

Current Ratio

6.09

LABP Investor Care

Buy Backs (1Y)

22.58%

Diluted EPS (TTM)

-3.48

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	0	72.0M	36.0M	18.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Landos Biopharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 28, 2023	bassaganya-riera josep	sold	-	-	-786,299	-
Feb 28, 2023	bassaganya-riera josep	sold	-	-	-3,470,740	-
Feb 28, 2023	bassaganya-riera josep	sold	-	-	-1,463,830	-
Sep 23, 2022	rtw investments, lp	sold	-207,000	0.69	-300,000	-
Aug 05, 2022	bassaganya-riera josep	gifted	-	-	500,000	-
Aug 05, 2022	bassaganya-riera josep	gifted	-	-	-500,000	-
Mar 23, 2022	bassaganya-riera josep	gifted	-	-	-650,000	-
Dec 28, 2021	bassaganya-riera josep	gifted	-	-	-1,000,000	-
Dec 20, 2021	bassaganya-riera josep	sold	-157,804	4.754	-33,194	-
Dec 17, 2021	bassaganya-riera josep	sold	-174,096	4.836	-36,000	-

Which funds bought or sold LABP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 17, 2024	DELTEC ASSET MANAGEMENT LLC	new	-	1,074,000	1,074,000	0.21%
Feb 26, 2024	PERCEPTIVE ADVISORS LLC	unchanged	-	-327,138	5,442,390	0.12%
Feb 14, 2024	Royal Bank of Canada	sold off	-100	-5,000	-	-%
Feb 14, 2024	MACQUARIE GROUP LTD	unchanged	-	-3,000	54,000	-%
Feb 13, 2024	RENAISSANCE TECHNOLOGIES LLC	added	9.75	1,000	41,000	-%
Feb 13, 2024	GEODE CAPITAL MANAGEMENT, LLC	unchanged	-	-2,647	46,130	-%
Feb 13, 2024	BlackRock Inc.	unchanged	-	-9.00	154	-%
Feb 13, 2024	Tower Research Capital LLC (TRC)	sold off	-100	-4,578	-	-%
Feb 13, 2024	ACADIAN ASSET MANAGEMENT LLC	unchanged	-	-	-	-%
Feb 12, 2024	JPMORGAN CHASE & CO	unchanged	-	-12.00	216	-%

Are Funds Buying or Selling LABP?

Are funds buying LABP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LABP

No. of Funds

Unveiling Landos Biopharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	perceptive advisors llc	47.7%	1,486,991	SC 13D/A
Apr 10, 2024	xontogeny, llc	9.9%	309,092	SC 13D/A
Feb 14, 2024	bassaganya-riera josep	0%	0	SC 13G/A
Mar 30, 2023	perceptive advisors llc	47.7%	14,869,915	SC 13D/A
Mar 30, 2023	xontogeny, llc	9.9%	3,090,924	SC 13D/A
Feb 14, 2023	bassaganya-riera josep	14.2%	5,720,868	SC 13G/A
Jan 13, 2023	perceptive advisors llc	36.9%	14,869,915	SC 13D/A
Nov 03, 2022	rtw investments, lp	0%	0	SC 13D/A
Oct 31, 2022	rtw investments, lp	7.83%	3,150,722	SC 13D/A
Oct 06, 2022	rtw investments, lp	9.07%	3,650,722	SC 13D/A

Recent SEC filings of Landos Biopharma, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	DEFM14A	DEFM14A
Apr 16, 2024	10-K/A	Annual Report
Apr 15, 2024	PREM14A	PREM14A
Apr 10, 2024	SC 13D/A	13D - Major Acquisition
Apr 10, 2024	SC 13D/A	13D - Major Acquisition
Mar 26, 2024	DEFA14A	DEFA14A
Mar 25, 2024	DEFA14A	DEFA14A
Mar 25, 2024	DEFA14A	DEFA14A
Mar 25, 2024	8-K	Current Report
Mar 21, 2024	S-8	Employee Benefits Plan

Peers (Alternatives to Landos Biopharma, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Landos Biopharma, Inc. News

Latest updates

Landos Biopharma, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q4	2021Q4	2021Q3	2021Q2
Revenue	-	-	-	-	18,000,000
Operating Expenses	-68.1%	6,513,000	20,395,500	12,403,000	14,118,000
S&GA Expenses	-55.4%	3,099,000	6,951,500	3,059,000	2,596,000
R&D Expenses	-74.6%	3,414,000	13,444,000	9,344,000	11,522,000
EBITDA Margin	1.1%	-2.08	-2.10	-0.81	-0.34
Interest Expenses	-	1,281,000	-	-	-
Earnings Before Taxes	74.0%	-5,232,000	-20,097,000	-12,604,000	4,097,000
EBT Margin	-2.2%	-2.18	-2.13	-0.82	-0.35
Net Income	74.0%	-5,232,000	-20,097,000	-12,604,000	4,097,000
Net Income Margin	-2.2%	-2.18	-2.13	-0.82	-0.35
Free Cashflow	69.2%	-3,699,000	-12,020,000	-12,108,000	9,251,000

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet													(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	-12.0%	38,040	43,230	46,285	51,184	45,253	49,488	58,038	77,610	92,879	105,098	118,291	110,210	30,332
Current Assets	-12.0%	38,040	43,230	46,285	51,184	45,253	49,488	58,038	77,359	92,146	104,318	117,727	109,745	29,888
Cash Equivalents	-11.6%	37,499	42,408	44,049	45,244	36,640	28,880	19,241	11,288	8,305	17,893	18,687	8,572	2,416
Net PPE	-	-	-	-	-	-	-	-	224	707	780	564	465	444
Liabilities	12.3%	6,249	5,566	3,015	4,160	6,122	5,475	6,510	15,507	16,611	11,180	12,679	9,031	11,310
Current Liabilities	12.3%	6,249	5,566	3,015	4,160	6,122	5,475	6,510	15,507	16,611	11,095	12,530	8,819	11,034
Shareholder's Equity	-15.6%	31,791	37,664	43,270	47,024	39,131	44,013	51,528	62,103	76,268	93,918	105,612	101,179	-
Retained Earnings	-4.2%	-155,400	-149,200	-143,383	-139,461	-133,427	-128,200	-120,299	-109,000	-94,151	-74,054	-61,450	-65,547	-55,729
Additional Paid-In Capital	0.1%	187,122	186,877	186,629	186,094	172,575	172,016	171,816	171,182	170,241	167,440	166,805	166,429	1,633
Shares Outstanding	0%	3,117	3,117	3,117	3,117	4,025	4,025	4,025	4,025	4,025	3,666	2,988	2,607	-
Float	-	-	-	5,600	-	-	-	8,500	-	-	-	89,900	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	-123.0%	-4,969	-2,228	-5,110	-8,170	-3,699	-7,573	-17,997	-16,502	-12,057	-11,844	9,400	-12,560	-8,391	-5,379	-5,824	-3,368
Share Based Compensation	-1.2%	245	248	254	224	196	200	634	941	2,428	355	312	1,023	833	-	-	-
Cashflow From Investing	-90.1%	63.00	634	3,974	3,104	11,471	17,212	25,871	19,506	1,796	10,831	715	-72,048	6,930	3,464	2,030	1,707
Cashflow From Financing	-	-	-	-99.00	13,666	-	-	-	-	624	219	-	90,764	-	-	-	-
Buy Backs	-	-	-	-	3,000	-	-	-	-	-	-	-	-	-	-	-	-

LABP Income Statement

2023-12-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 11,999	$ 25,680
General and administrative	10,728	14,881
Total operating expenses	22,727	40,561
Loss from operations	(22,727)	(40,561)
Other income:
(Loss) gain from foreign exchange	(44)	26
Interest and other income, net	836	1,259
Other income, net	792	1,285
Net loss	$ (21,935)	$ (39,276)
Net loss per share, basic	$ (3.5)	$ (9.76)
Net loss per share, diluted	$ (3.5)	$ (9.76)
Weighted average shares used to compute net loss per share, basic	6,275,856	4,025,489
Weighted average shares used to compute net loss per share, diluted	6,275,856	4,025,489
Net loss	$ (21,935)	$ (39,276)
Unrealized gain on available-for-sale securities	57	168
Comprehensive loss	$ (21,878)	$ (39,108)

LABP Balance Sheet

2023-12-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 37,499	$ 36,640
Marketable securities, available for-sale	0	7,762
Restricted cash	50	0
Prepaid expenses and other current assets	491	851
Total current assets	38,040	45,253
Total assets	38,040	45,253
Current liabilities:
Accounts payable	1,375	3,435
Accrued liabilities	4,874	2,687
Total current liabilities	6,249	6,122
Total liabilities	6,249	6,122
Stockholders' (deficit) equity:
Preferred stock, $0.01 par value; 10,000,000 shares authorized, no shares issued and outstanding as of December 31, 2023 and 2022	0	0
Common stock, $0.01 par value; 200,000,000 shares authorized, 3,116,729 and 4,025,489 shares issued and outstanding as of December 31, 2023 and 2022	31	40
Additional paid-in-capital	187,122	172,575
Accumulated other comprehensive loss	(0)	(57)
Accumulated deficit	(155,362)	(133,427)
Total stockholders' equity	31,791	39,131
Total liabilities and stockholders' equity	$ 38,040	$ 45,253

About Landos Biopharma, Inc.

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer's disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.

CEO	Mr. Gregory Oakes
WEBSITE	https://landosbiopharma.com
INDUSTRY	Biotechnology
EMPLOYEES	22

Landos Biopharma, Inc. Frequently Asked Questions

What is the ticker symbol for Landos Biopharma, Inc.? What does LABP stand for in stocks?

LABP is the stock ticker symbol of Landos Biopharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Landos Biopharma, Inc. (LABP)?

As of Fri Apr 26 2024, market cap of Landos Biopharma, Inc. is 69.53 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LABP stock?

You can check LABP's fair value in chart for subscribers.

What is the fair value of LABP stock?

You can check LABP's fair value in chart for subscribers. The fair value of Landos Biopharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Landos Biopharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LABP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Landos Biopharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether LABP is over valued or under valued. Whether Landos Biopharma, Inc. is cheap or expensive depends on the assumptions which impact Landos Biopharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LABP.

What is Landos Biopharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, LABP's PE ratio (Price to Earnings) is -3.17 and Price to Sales (PS) ratio is 3.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LABP PE ratio will change depending on the future growth rate expectations of investors.